Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer

被引：0

作者：

Strumberg, D. ^{[1
]}

Schultheis, B. ^{[1
]}

Scheulen, M. E. ^{[2
]}

Hilger, R. A. ^{[2
]}

Krauss, J. ^{[2
]}

Marschner, N. ^{[3
]}

Lordick, F. ^{[4
]}

Bach, F. ^{[5
]}

Reuter, D. ^{[5
]}

Edler, L. ^{[6
]}

Mross, K. ^{[7
]}

机构：

[1] Univ Bochum, Dept Hematol & Med Oncol, Marienhosp Herne, D-44625 Herne, Germany

[2] Univ Hosp Essen, Dept Med Oncol, Essen, Germany

[3] Onkol Schwerpunktpraxis Freiburg, Freiburg, Germany

[4] Univ Hosp Munich, Klinikum Rechts Isar, Dept Hematol & Med Oncol, Munich, Germany

[5] Oncosci AG, Wedel, Germany

[6] German Canc Res Ctr, D-6900 Heidelberg, Germany

[7] Univ Freiburg, Tumor Biol Ctr, Freiburg, Germany

来源：

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS | 2010年 / 48卷 / 07期

关键词：

pancreatic cancer; nimotuzumab; EGFR antibody; clinical trial; advanced disease; CLINICAL BENEFIT; GEMCITABINE; MUTATIONS; SURVIVAL; TRIAL;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：473 / 475

页数：3

共 8 条

[1] Nimotuzumab: Evidence of clinical benefit without rash [J].

Allan, DGP .

ONCOLOGIST, 2005, 10 (09) :760-761

[2] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].

Burris, HA ;

Moore, MJ ;

Andersen, J ;

Green, MR ;

Rothenberg, ML ;

Madiano, MR ;

Cripps, MC ;

Portenoy, RK ;

Storniolo, AM ;

Tarassoff, P ;

Nelson, R ;

Dorr, FA ;

Stephens, CD ;

VanHoff, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413

[3] Cancer statistics, 2008 [J].

Jemal, Ahmedin ;

Siegel, Rebecca ;

Ward, Elizabeth ;

Hao, Yongping ;

Xu, Jiaquan ;

Murray, Taylor ;

Thun, Michael J. .

CA-A CANCER JOURNAL FOR CLINICIANS, 2008, 58 (02) :71-96

[4]

Lam C, 2009, FUTURE ONCOL, V5, P1349, DOI [10.2217/fon.09.119, 10.2217/FON.09.119]

[5] Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplilications, and KRAS mutations on survival of pancreatic adenocarcinoma [J].

Lee, Jeeyun ;

Jang, Kee-Taek ;

Ki, Chang-Seok ;

Lim, Taekyu ;

Park, Young Suk ;

Lim, Ho Yeong ;

Choi, Dong-Wook ;

Kaing, Won Ki ;

Park, Keunchil ;

Park, Joon Oh .

CANCER, 2007, 109 (08) :1561-1569

[6] Pancreatic cancer [J].

Li, DH ;

Xie, KP ;

Wolff, R ;

Abbruzzese, JL .

LANCET, 2004, 363 (9414) :1049-1057

[7] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[8] Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group [J].

Moore, Malcolm J. ;

Goldstein, David ;

Hamm, John ;

Figer, Arie ;

Hecht, Joel R. ;

Gallinger, Steven ;

Au, Heather J. ;

Murawa, Pawel ;

Walde, David ;

Wolff, Robert A. ;

Campos, Daniel ;

Lim, Robert ;

Ding, Keyue ;

Clark, Gary ;

Voskoglou-Nomikos, Theodora ;

Ptasynski, Mieke ;

Parulekar, Wendy .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) :1960-1966

← 1 →